Curaleaf Completes Four 20 Pharma Buyout, Eyes European Growth

A Transatlantic Cannabis Empire Takes Shape

In a move that cements its position as the most aggressive international player in the cannabis space, Curaleaf Holdings completed its full acquisition of Germany's Four 20 Pharma on April 30, 2026. The deal gives Curaleaf 100 percent ownership of the EU-GMP and GDP licensed medical cannabis producer and distributor — and a launchpad for what the company envisions as a pan-European cannabis platform.

The acquisition closes out a transaction that began in September 2022, when Curaleaf paid approximately €19.7 million for a 55 percent majority stake in the German company. The remaining 45 percent has now been absorbed, giving Curaleaf complete operational control over Four 20 Pharma's manufacturing, distribution, and regulatory infrastructure.

Why Germany Matters

Germany is not just another European market. It is the continent's largest economy and has established itself as the de facto hub of European medical cannabis. Since legalizing medical cannabis in 2017, Germany has built a robust regulatory framework that has attracted investment from across the globe.

The German medical cannabis market has grown rapidly, driven by a relatively large patient population and a reimbursement system that integrates cannabis into the broader healthcare framework. Unlike many other European nations where medical cannabis exists in a regulatory gray zone, Germany offers a structured pathway from cultivation to patient access.

Four 20 Pharma has been a significant player in this ecosystem. The company holds EU-GMP certification — the gold standard for pharmaceutical manufacturing in Europe — along with GDP (Good Distribution Practice) credentials that enable it to move product across EU member states.

The Torsten Greif Factor

The acquisition was accompanied by a strategic board appointment that signals Curaleaf's long-term European ambitions. On May 1, 2026, Curaleaf announced that Torsten Greif — the founder of Four 20 Pharma who originally guided the sale of the majority stake to Curaleaf — would join the company's board of directors.

Boris Jordan, Curaleaf's chairman and CEO, described Greif's expertise as essential to the company's European scaling strategy. Greif brings deep knowledge of the German regulatory environment and established relationships across the European medical cannabis supply chain.

The appointment is a clear signal that Curaleaf views Europe not as a side project but as a core pillar of its future growth. Having the founder of its most important European asset at the board level ensures that regional expertise informs global strategy.

Beyond Germany: The UK and Poland Push

Building on Four 20 Pharma's reputation in Germany, Curaleaf has launched the Four 20 brand in the United Kingdom and Poland — two markets that represent very different but equally compelling opportunities.

The UK medical cannabis market, while still relatively small compared to Germany, has been growing steadily since legalization in 2018. Curaleaf's UK arm recently achieved a notable milestone by beginning domestic manufacture of medical cannabis suppositories and pessaries — a first for the British market. This move into specialist formulations signals a maturation beyond imported flower products and positions Curaleaf as a manufacturer, not just a distributor, in the UK market.

Poland, with a population of 38 million and a relatively recent opening to medical cannabis, represents a longer-term bet. The country's medical cannabis infrastructure is still developing, but early movers with established brands and EU-GMP supply chains stand to capture significant market share as the regulatory framework matures.

The Numbers Tell the Story

Curaleaf's international division reported €172.5 million in revenue for full-year 2025 — a 63 percent increase over 2024. The division is now operating at an annualized rate exceeding €200 million, making it one of the largest cannabis operations in Europe by revenue.

These figures reflect a broader trend in the global cannabis industry: while the North American market grapples with oversupply, pricing pressure, and regulatory uncertainty, European medical markets are delivering consistent growth with higher margins and more predictable regulatory environments.

For Curaleaf, the math is straightforward. European medical cannabis commands premium pricing, benefits from healthcare system integration, and faces less competition than the saturated U.S. market. The Four 20 Pharma acquisition gives the company a vertically integrated European supply chain that runs from Portuguese and Canadian cultivation facilities through German manufacturing and into retail markets across the EU and UK.

Competitive Landscape

Curaleaf is not operating in a vacuum. Tilray Brands, Organigram, and several European-born companies are also pursuing continental expansion. However, Curaleaf's strategy of acquiring established local operators — rather than building from scratch — has given it a speed advantage.

The Four 20 Pharma deal exemplifies this approach. Rather than navigating Germany's complex pharmaceutical regulations as a foreign entrant, Curaleaf acquired a company that had already done the hard work of obtaining EU-GMP certification, building distribution relationships, and establishing brand recognition among prescribers and patients.

What This Means for the Industry

The Curaleaf-Four 20 Pharma deal is a bellwether for the broader cannabis industry's international ambitions. It demonstrates that the most sophisticated cannabis operators are thinking globally, building supply chains that span continents, and positioning themselves for a future where medical cannabis is a normalized pharmaceutical category in major world economies.

For the European market specifically, the deal signals continued consolidation. As regulatory barriers favor companies with established compliance infrastructure, smaller operators will face pressure to either scale up or sell to larger players with deeper pockets and broader geographic reach.

The cannabis industry in 2026 is increasingly defined by this dynamic — the gap between well-capitalized, internationally diversified companies and smaller, single-market operators is widening. Curaleaf's European bet is a calculated wager that this gap will only grow.

Looking Ahead

Curaleaf has signaled its intent to extend the Four 20 brand into additional European markets using the same quality and compliance framework that established the brand's reputation in Germany. With Italy, France, and several Eastern European nations at various stages of medical cannabis liberalization, the potential addressable market continues to expand.

The June 2026 DEA hearings in the United States will also be relevant to Curaleaf's strategy. If the domestic regulatory environment becomes more favorable, the company could leverage its European infrastructure to create a truly global supply chain. If U.S. reform stalls, Europe offers an increasingly attractive alternative growth engine.

Either way, the completion of the Four 20 Pharma acquisition marks a pivotal moment — not just for Curaleaf, but for the maturation of cannabis as a global industry.

For consumers ready to act on what they have read, the next step is finding a licensed retailer that actually carries quality product. Browse verified cannabis dispensaries by state and city to compare hours, menus, and reviews — every listing on Budpedia is license-checked.